News

Researchers have identified markers that indicate the presence of Parkinson’s disease in patients an average of 7 years before the disease presents clinically.

The findings of this study shed new light on processes such as learning and memory but also the development of blinding conditions.

According to Regeneron, the approval was based on data in the PULSAR and PHOTON trials, in which the drug demonstrated clinically equivalent vision gains to aflibercept Injection 2 mg that were maintained with fewer injections.

Adverum Biotechnologies, Inc. provided an update on the company’s ongoing Phase 2 LUNA trial evaluating ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD).

The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date for APP13007 of March 4, 2024.

Astellas Pharma Inc. announced the European Medicines Agency (EMA) has accepted for regulatory review the marketing authorization application (MAA) for Iveric Bio’s avacincaptad pegol (ACP).

Clinicians should be alert to the fact that while artificial intelligence (AI) is capable of generating ideas and references, it is crucial to thoroughly vet and fact-check any medical research content that AI produces.

Without treatment, severe visual impairment can occur; the first-line treatment for these cases is anti-vascular endothelial growth factor therapy (VEGF).

The study met its primary efficacy endpoint for the neovascular age-related macular degeneration (nAMD) treatment.

According to Orbis International, the technology proves to be a practical solution in low-resource communities for tackling the leading cause of vision loss among working-age adults.

According to Regeneron, visual gains and safety of aflibercept 8 mg remained consistent with the established profile of aflibercept 2 mg injection.

The plan is intended to upgrade Vitagrus’ manufacturing process so that it can ultimately handle the global market supply.

Eye symptoms such as dry, itchy, red, painful, watery, and gritty eyes can happen before the smoke is even noticeable.

In this study, the investigators retrospectively reviewed all study patients who underwent pars plana vitrectomy with silicone oil tamponade for postsurgical endophthalmitis.

Carl Regillo, MD, FACS, FASRS, spoke with our team following the annual ASRS meeting in Seattle, Washington to share insights from his presentation titled, "Modulation of Macrophages and Complement Dysfunction in Non-exudative AMD utilizing novel, sialic-acid coated nanoparticles." Aviceda Therapeutics is unlocking the proteogenomic code of AMD to target proteins and pathways linked to macular degeneration.

Kerrie Brady, Chief Executive Officer and President of OcuTerra Therapeutics shared updates from the company including the development of OTT166 at the 2023 ASRS annual meeting.

An industrial engineer and entrepreneur, George Glady was a founder of Euclid Systems Corp. and developed the concept of the Ortho-K contact lenses.

Oculis Holding AG announced, if approved, OCS-01 has the potential to become a new standard of care as the first once-daily, topical, preservative-free corticosteroid for treating inflammation and pain following ocular surgery.

David Lally, MD, spoke with our team about the ZETA-1 phase 2 trial efficacy results for APX3330, a novel, oral ref-1 inhibitor for the treatment of diabetic retinopathy at the 2023 ASRS annual meeting.

An experienced dermatologist blinded to clinical data performed the NVC using a videocapillaroscope VideoCap 3.0 (DSMedica) at 200× magnification in the study.

Intergalactic Therapeutics, based in Cambridge, MA, announced its closing after less than 2 years since the company's launch in 2021.

Veena Raiji, MD, MPH, spoke with our team about long-term outcomes of eyes requiring IOP-lowering medication in the PALADIN trial at the 2023 ASRS annual meeting.

Choroideremia shares traits with retinitis pigmentosa (RP). Both diseases are caused by underlying inherited gene defects and result in the death of photoreceptors within the retina.

J. Fernando Arevalo, MD, PhD, FACS, FASRS, a member of Modern Retina's editorial advisory board, spoke with us about clinical characteristics of macular holes that close without surgery.

The investigators explored the effects of the following covariates on development of AMD: sex, ethnicity, smoking history, fluoxetine use, obesity, diabetes mellitus, and hypertension.

In addition to the educational offerings, the program offers opportunities for relaxation and spiritual and family-building events.

Of the 484 hospitals, 22 are named to the national Honor Roll for ranking in one or more of the specialties that US News evaluates.

At the 2023 ASRS annual meeting in Seattle, Washington, Michael Singer, MD, spoke with our team about the Starlight Study, which is an optogenetic study looking at patients who had Stargardt disease.